ReviewFrontiers in pharmacology2018

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.

Alessandro Ottaiano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.